中性粒細胞與淋巴細胞比值在慢性阻塞性肺疾病中的應用研究進展_Chinese Journal of Respiratory and Critical Care Medicine

Authors：

李四香 , 趙爽 ,  李為民

四川大學華西醫院呼吸與危重癥醫學科（四川成都 610041）;

Corresponding?author：

李為民, Email: weimin003@scu.edu.cn

Keywords：

DOI：

10.7507/1671-6205.201903044

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 李四香, 趙爽, 李為民. 中性粒細胞與淋巴細胞比值在慢性阻塞性肺疾病中的應用研究進展. Chinese Journal of Respiratory and Critical Care Medicine, 2020, 19(3): 304-308. doi: 10.7507/1671-6205.201903044 Copy

1.	Collaborators GBDCRD. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med, 2017, 5(9): 691-706.
2.	Collaborators GBDCoD. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, 2018, 392(10159): 1736-1788.
3.	Wang C, Xu J, Yang L, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health CPH study): a national cross-sectional study. Lancet, 2018, 391(10131): 1706-1717.
4.	Sanchez-Salcedo P, de Torres JP. BODE Index: a good quality of life marker in chronic obstructive pulmonary disease patients. Arch Bronconeumol, 2015, 51(7): 311-312.
5.	Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med, 2004, 350(10): 1005-1012.
6.	Puhan MA, Garcia-Aymerich J, Frey M, et al. Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE index and the ADO index. Lancet, 2009, 374(9691): 704-711.
7.	Hoogendoorn M, Feenstra TL, Boland M, et al. Prediction models for exacerbations in different COPD patient populations: comparing results of five large data sources. Int J Chron Obstruct Pulmon Dis, 2017, 12: 3183-3194.
8.	Regan EA, Hersh CP, Castaldi PJ, et al. Omics and the search for blood biomarkers in COPD: insights from COPD Gene. Am J Respir Cell Mol Bio, 2019, 61(2): 143-149.
9.	Paliogiannis P, Fois AG, Sotgia S, et al. Neutrophil to lymphocyte ratio and clinical outcomes in COPD: recent evidence and future perspectives. Eur Respir Rev, 2018, 27(147): pii: 170113.
10.	Liu J, Liu J, Zou Y. Relationship between neutrophil-lymphocyte ratio and short-term prognosis in the chronic obstructive pulmonary patients with acute exacerbation. Biosci Rep, 2019, 39(5): pii: BSR20190675.
11.	Xiong W, Xu M, Zhao Y, et al. Can we predict the prognosis of COPD with a routine blood test?. Int J Chron Obstruct Pulmon Dis, 2017, 12: 615-625.
12.	Ye Z, Ai X, Liao Z, et al. The prognostic values of neutrophil to lymphocyte ratio for outcomes in chronic obstructive pulmonary disease. Medicine (Baltimore), 2019, 98(32): e16859.
13.	Forget P, Khalifa C, Defour JP, et al. What is the normal value of the neutrophil-to-lymphocyte ratio?. BMC Res Notes, 2017, 10(1): 12.
14.	Bressi E, Mangiacapra F, Ricottini E, et al. Impact of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio on 5-year clinical outcomes of patients with stable coronary artery disease undergoing elective percutaneous coronary intervention. J Cardiovasc Transl Res, 2018, 11(6): 517-523.
15.	Fujimoto Y, Ozawa H, Higuchi T, et al. Improved prognosis of low baseline neutrophil-to-lymphocyte ratio is significantly exclusive in breast cancer patients with high absolute counts of lymphocytes. Mol Clin Oncol, 2019, 10(2): 275-284.
16.	Templeton AJ, Rodriguez-Lescure A, Ruiz A, et al. Prognostic role for the derived neutrophil-to-lymphocyte ratio in early breast cancer: a GEICAM/9906 substudy. Clin Transl Oncol, 2018, 20(12): 1548-1556.
17.	Li MX, Liu XM, Zhang XF, et al. Prognostic role of neutrophil-to-lymphocyte ratio in colorectal cancer: a systematic review and meta-analysis. Int J Cancer, 2014, 134(10): 2403-2413.
18.	Chua W, Charles KA, Baracos VE, et al. Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. Br J Cancer, 2011, 104(8): 1288-1295.
19.	Deng Q, He B, Liu X, et al. Prognostic value of pre-operative inflammatory response biomarkers in gastric cancer patients and the construction of a predictive model. J Transl Med, 2015, 13: 66.
20.	Mei Z, Shi L, Wang B, et al. Prognostic role of pretreatment blood neutrophil-to-lymphocyte ratio in advanced cancer survivors: a systematic review and meta-analysis of 66 cohort studies. Cancer Treat Rev, 2017, 58: 1-13.
21.	Diem S, Schmid S, Krapf M, et al. Neutrophil-to-lymphocyte ratio (NLR) and Platelet-to-lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Lung Cancer, 2017, 111: 176-181.
22.	Bagley SJ, Kothari S, Aggarwal C, et al. Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer. Lung Cancer, 2017, 106: 1-7.
23.	Zhu S, Yang J, Cui XW, et al. Preoperative platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio as predictors of clinical outcome in patients with gallbladder cancer. Sci Rep, 2019, 9(1): 1823.
24.	Huang YK, Liu AH, Liang L, et al. Diagnostic value of blood parameters for community-acquired pneumonia. Int Immunopharmacol, 2018, 64: 10-15.
25.	Farah R, Ibrahim R, Nassar M, et al. The neutrophil/lymphocyte ratio is a better addition to C-reactive protein than CD64 index as a marker for infection in COPD. Panminerva Med, 2017, 59(3): 203-209.
26.	Yousef AM, Alkhiary W. Role of neutrophil to lymphocyte ratio in prediction of acute exacerbation of chronic obstructive pulmonary disease. Egyp J Chest Dis Tubercul, 2017, 66(1): 43-48.
27.	Sakurai K, Chubachi S, Irie H, et al. Clinical utility of blood neutrophil-lymphocyte ratio in Japanese COPD patients. BMC Pulm Med, 2018, 18(1): 65.
28.	Lee SJ, Lee HR, Lee TW, et al. Usefulness of neutrophil to lymphocyte ratio in patients with chronic obstructive pulmonary disease: a prospective observational study. Korean J Intern Med, 2016, 31(5): 891-898.
29.	Yao C, Liu X, Tang Z. Prognostic role of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio for hospital mortality in patients with AECOPD. Int J Chron Obstruct Pulmon Dis, 2017, 12: 2285-2290.
30.	Paliogiannis P, Fois AG, Sotgia S, et al. The neutrophil-to-lymphocyte ratio as a marker of chronic obstructive pulmonary disease and its exacerbations: a systematic review and meta-analysis. Eur J Clin Invest, 2018, 48(8): e12984.
31.	Taylan M, Demir M, Kaya H, et al. Alterations of the neutrophil-lymphocyte ratio during the period of stable and acute exacerbation of chronic obstructive pulmonary disease patients. Clin Respir J, 2017, 11(3): 311-317.
32.	Furutate R, Ishii T, Motegi T, et al. The neutrophil to lymphocyte ratio is related to disease severity and exacerbation in patients with chronic obstructive pulmonary disease. Intern Med, 2016, 55(3): 223-229.
33.	Teng F, Ye H, Xue T. Predictive value of neutrophil to lymphocyte ratio in patients with acute exacerbation of chronic obstructive pulmonary disease. PLos One, 2018, 13(9): e0204377.
34.	Coban Agca M, Aksoy E, Duman D, et al. Does eosinophilia and neutrophil to lymphocyte ratio affect hospital re-admission in cases of COPD exacerbation?. Tuberk Toraks, 2017, 65(4): 282-290.
35.	唐文娟, 李建強. 中性粒細胞/淋巴細胞比值在慢性阻塞性肺疾病合并肺動脈高壓患者中的臨床意義. 山西醫科大學學報, 2018, 49(11): 1329-1333.
36.	Barnes PJ. Inflammatory endotypes in COPD. Allergy, 2019, 74(7): 1249-1256.
37.	Duman D, Aksoy E, Agca MC, et al. The utility of inflammatory markers to predict readmissions and mortality in COPD cases with or without eosinophilia. Int J Chron Obstruct Pulmon Dis, 2015, 10: 2469-2478.
38.	Aksoy E, Karakurt Z, Gungor S, et al. Neutrophil to lymphocyte ratio is a better indicator of COPD exacerbation severity in neutrophilic endotypes than eosinophilic endotypes. Int J Chron Obstruct Pulmon Dis, 2018, 13: 2721-2730.
39.	Acarturk Tuncay E, Karakurt Z, Aksoy E, et al. Eosinophilic and non-eosinophilic COPD patients with chronic respiratory failure: neutrophil-to-lymphocyte ratio as an exacerbation marker. Int J Chron Obstruct Pulmon Dis, 2017, 12: 3361-3370.
40.	Rovina N, Dima E, Gennimata SA, et al. Neutrophil/lymphocyte (NLR) ratio in infectious acute exacerbations of COPD (AECOPD). Eur Respir J, 2014, 44: 3997.
41.	Stockley RA, Halpin DMG, Celli BR, et al. COPD biomarkers and their interpretation. Am J Respir Crit Care Med, 2019, 199(10): 1195-1204.
42.	Celli BR, Anderson JA, Brook R, et al. Serum biomarkers and outcomes in patients with moderate COPD: a substudy of the randomised SUMMIT trial. BMJ Open Respir Res, 2019, 6(1): e000431.
43.	Bal SM, Bernink JH, Nagasawa M, et al. IL-1 beta, IL-4 and IL-12 control the fate of group 2 innate lymphoid cells in human airway inflammation in the lungs. Nat Immunol, 2016, 17(6): 636-645.
44.	Thomsen M, Ingebrigtsen T, Marott J, et al. Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease. JAMA, 2013, 309(22): 2353-2361.
45.	Agusti A, Edwards LD, Rennard SI, et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PlLos One, 2012, 7(5): e37483.
46.	Zhang J, Bai C. The significance of serum interleukin-8 in acute exacerbations of chronic obstructive pulmonary disease. Tanaffos, 2018, 17(1): 13-21.
47.	Ronnow SR, Sand JMB, Langholm LL, et al. Type IV collagen turnover is predictive of mortality in COPD: a comparison to fibrinogen in a prospective analysis of the ECLIPSE cohort. Respir Res, 2019, 20(1): 63.
48.	Obeidat M, Li X, Burgess S, et al. Surfactant protein D is a causal risk factor for COPD: results of Mendelian randomisation. Eur Respir J, 2017, 50(5): pii: 1700657.
49.	Hassan NB, Abo-ElMagd NM, Ahmed NO. Neutrophil CD64 expression and other laboratory biomarkers in discriminating bacterial versus non bacterial acute exacerbation chronic obstructive pulmonary disease. Egypt J Immunol, 2018, 25(1): 171-179.
50.	Titova E, Aune MW, Fonn K, et al. Neutrophil CD64 expression as a diagnostic marker in patients hospitalized with exacerbations of COPD: a prospective observational study. Lung, 2015, 193(5): 717-724.
51.	Mendy A, Forno E, Niyonsenga T, et al. Blood biomarkers as predictors of long-term mortality in COPD. Clin Respir J, 2018, 12(5): 1891-1899.
52.	Mohamed-Hussein A, Aly S, Zahran A, et al. Neutrophil CD64 versus neutrophil/lymphocyte ratio (NLR) as markers predicting in-hospital outcome in acute exacerbation of COPD. Eur Respir J, 2017, 50: PA4095.
53.	Gunay E, Sarinc Ulasli S, Akar O, et al. Neutrophil-to-lymphocyte ratio in chronic obstructive pulmonary disease: a retrospective study. Inflammation, 2014, 37(2): 374-380.
54.	Leung JM, Obeidat M, Sadatsafavi M, et al. Introduction to precision medicine in COPD. Eur Respir J, 2019, 53(4): pii: 1802460.
55.	Washko GR, Parraga G. COPD biomarkers and phenotypes: opportunities for better outcomes with precision imaging. Eur Respir J, 2018, 52(5): pii: 1801570.

1. Collaborators GBDCRD. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med, 2017, 5(9): 691-706.
2. Collaborators GBDCoD. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, 2018, 392(10159): 1736-1788.
3. Wang C, Xu J, Yang L, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health CPH study): a national cross-sectional study. Lancet, 2018, 391(10131): 1706-1717.
4. Sanchez-Salcedo P, de Torres JP. BODE Index: a good quality of life marker in chronic obstructive pulmonary disease patients. Arch Bronconeumol, 2015, 51(7): 311-312.
5. Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med, 2004, 350(10): 1005-1012.
6. Puhan MA, Garcia-Aymerich J, Frey M, et al. Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE index and the ADO index. Lancet, 2009, 374(9691): 704-711.
7. Hoogendoorn M, Feenstra TL, Boland M, et al. Prediction models for exacerbations in different COPD patient populations: comparing results of five large data sources. Int J Chron Obstruct Pulmon Dis, 2017, 12: 3183-3194.
8. Regan EA, Hersh CP, Castaldi PJ, et al. Omics and the search for blood biomarkers in COPD: insights from COPD Gene. Am J Respir Cell Mol Bio, 2019, 61(2): 143-149.
9. Paliogiannis P, Fois AG, Sotgia S, et al. Neutrophil to lymphocyte ratio and clinical outcomes in COPD: recent evidence and future perspectives. Eur Respir Rev, 2018, 27(147): pii: 170113.
10. Liu J, Liu J, Zou Y. Relationship between neutrophil-lymphocyte ratio and short-term prognosis in the chronic obstructive pulmonary patients with acute exacerbation. Biosci Rep, 2019, 39(5): pii: BSR20190675.
11. Xiong W, Xu M, Zhao Y, et al. Can we predict the prognosis of COPD with a routine blood test?. Int J Chron Obstruct Pulmon Dis, 2017, 12: 615-625.
12. Ye Z, Ai X, Liao Z, et al. The prognostic values of neutrophil to lymphocyte ratio for outcomes in chronic obstructive pulmonary disease. Medicine (Baltimore), 2019, 98(32): e16859.
13. Forget P, Khalifa C, Defour JP, et al. What is the normal value of the neutrophil-to-lymphocyte ratio?. BMC Res Notes, 2017, 10(1): 12.
14. Bressi E, Mangiacapra F, Ricottini E, et al. Impact of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio on 5-year clinical outcomes of patients with stable coronary artery disease undergoing elective percutaneous coronary intervention. J Cardiovasc Transl Res, 2018, 11(6): 517-523.
15. Fujimoto Y, Ozawa H, Higuchi T, et al. Improved prognosis of low baseline neutrophil-to-lymphocyte ratio is significantly exclusive in breast cancer patients with high absolute counts of lymphocytes. Mol Clin Oncol, 2019, 10(2): 275-284.
16. Templeton AJ, Rodriguez-Lescure A, Ruiz A, et al. Prognostic role for the derived neutrophil-to-lymphocyte ratio in early breast cancer: a GEICAM/9906 substudy. Clin Transl Oncol, 2018, 20(12): 1548-1556.
17. Li MX, Liu XM, Zhang XF, et al. Prognostic role of neutrophil-to-lymphocyte ratio in colorectal cancer: a systematic review and meta-analysis. Int J Cancer, 2014, 134(10): 2403-2413.
18. Chua W, Charles KA, Baracos VE, et al. Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. Br J Cancer, 2011, 104(8): 1288-1295.
19. Deng Q, He B, Liu X, et al. Prognostic value of pre-operative inflammatory response biomarkers in gastric cancer patients and the construction of a predictive model. J Transl Med, 2015, 13: 66.
20. Mei Z, Shi L, Wang B, et al. Prognostic role of pretreatment blood neutrophil-to-lymphocyte ratio in advanced cancer survivors: a systematic review and meta-analysis of 66 cohort studies. Cancer Treat Rev, 2017, 58: 1-13.
21. Diem S, Schmid S, Krapf M, et al. Neutrophil-to-lymphocyte ratio (NLR) and Platelet-to-lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Lung Cancer, 2017, 111: 176-181.
22. Bagley SJ, Kothari S, Aggarwal C, et al. Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer. Lung Cancer, 2017, 106: 1-7.
23. Zhu S, Yang J, Cui XW, et al. Preoperative platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio as predictors of clinical outcome in patients with gallbladder cancer. Sci Rep, 2019, 9(1): 1823.
24. Huang YK, Liu AH, Liang L, et al. Diagnostic value of blood parameters for community-acquired pneumonia. Int Immunopharmacol, 2018, 64: 10-15.
25. Farah R, Ibrahim R, Nassar M, et al. The neutrophil/lymphocyte ratio is a better addition to C-reactive protein than CD64 index as a marker for infection in COPD. Panminerva Med, 2017, 59(3): 203-209.
26. Yousef AM, Alkhiary W. Role of neutrophil to lymphocyte ratio in prediction of acute exacerbation of chronic obstructive pulmonary disease. Egyp J Chest Dis Tubercul, 2017, 66(1): 43-48.
27. Sakurai K, Chubachi S, Irie H, et al. Clinical utility of blood neutrophil-lymphocyte ratio in Japanese COPD patients. BMC Pulm Med, 2018, 18(1): 65.
28. Lee SJ, Lee HR, Lee TW, et al. Usefulness of neutrophil to lymphocyte ratio in patients with chronic obstructive pulmonary disease: a prospective observational study. Korean J Intern Med, 2016, 31(5): 891-898.
29. Yao C, Liu X, Tang Z. Prognostic role of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio for hospital mortality in patients with AECOPD. Int J Chron Obstruct Pulmon Dis, 2017, 12: 2285-2290.
30. Paliogiannis P, Fois AG, Sotgia S, et al. The neutrophil-to-lymphocyte ratio as a marker of chronic obstructive pulmonary disease and its exacerbations: a systematic review and meta-analysis. Eur J Clin Invest, 2018, 48(8): e12984.
31. Taylan M, Demir M, Kaya H, et al. Alterations of the neutrophil-lymphocyte ratio during the period of stable and acute exacerbation of chronic obstructive pulmonary disease patients. Clin Respir J, 2017, 11(3): 311-317.
32. Furutate R, Ishii T, Motegi T, et al. The neutrophil to lymphocyte ratio is related to disease severity and exacerbation in patients with chronic obstructive pulmonary disease. Intern Med, 2016, 55(3): 223-229.
33. Teng F, Ye H, Xue T. Predictive value of neutrophil to lymphocyte ratio in patients with acute exacerbation of chronic obstructive pulmonary disease. PLos One, 2018, 13(9): e0204377.
34. Coban Agca M, Aksoy E, Duman D, et al. Does eosinophilia and neutrophil to lymphocyte ratio affect hospital re-admission in cases of COPD exacerbation?. Tuberk Toraks, 2017, 65(4): 282-290.
35. 唐文娟, 李建強. 中性粒細胞/淋巴細胞比值在慢性阻塞性肺疾病合并肺動脈高壓患者中的臨床意義. 山西醫科大學學報, 2018, 49(11): 1329-1333.
36. Barnes PJ. Inflammatory endotypes in COPD. Allergy, 2019, 74(7): 1249-1256.
37. Duman D, Aksoy E, Agca MC, et al. The utility of inflammatory markers to predict readmissions and mortality in COPD cases with or without eosinophilia. Int J Chron Obstruct Pulmon Dis, 2015, 10: 2469-2478.
38. Aksoy E, Karakurt Z, Gungor S, et al. Neutrophil to lymphocyte ratio is a better indicator of COPD exacerbation severity in neutrophilic endotypes than eosinophilic endotypes. Int J Chron Obstruct Pulmon Dis, 2018, 13: 2721-2730.
39. Acarturk Tuncay E, Karakurt Z, Aksoy E, et al. Eosinophilic and non-eosinophilic COPD patients with chronic respiratory failure: neutrophil-to-lymphocyte ratio as an exacerbation marker. Int J Chron Obstruct Pulmon Dis, 2017, 12: 3361-3370.
40. Rovina N, Dima E, Gennimata SA, et al. Neutrophil/lymphocyte (NLR) ratio in infectious acute exacerbations of COPD (AECOPD). Eur Respir J, 2014, 44: 3997.
41. Stockley RA, Halpin DMG, Celli BR, et al. COPD biomarkers and their interpretation. Am J Respir Crit Care Med, 2019, 199(10): 1195-1204.
42. Celli BR, Anderson JA, Brook R, et al. Serum biomarkers and outcomes in patients with moderate COPD: a substudy of the randomised SUMMIT trial. BMJ Open Respir Res, 2019, 6(1): e000431.
43. Bal SM, Bernink JH, Nagasawa M, et al. IL-1 beta, IL-4 and IL-12 control the fate of group 2 innate lymphoid cells in human airway inflammation in the lungs. Nat Immunol, 2016, 17(6): 636-645.
44. Thomsen M, Ingebrigtsen T, Marott J, et al. Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease. JAMA, 2013, 309(22): 2353-2361.
45. Agusti A, Edwards LD, Rennard SI, et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PlLos One, 2012, 7(5): e37483.
46. Zhang J, Bai C. The significance of serum interleukin-8 in acute exacerbations of chronic obstructive pulmonary disease. Tanaffos, 2018, 17(1): 13-21.
47. Ronnow SR, Sand JMB, Langholm LL, et al. Type IV collagen turnover is predictive of mortality in COPD: a comparison to fibrinogen in a prospective analysis of the ECLIPSE cohort. Respir Res, 2019, 20(1): 63.
48. Obeidat M, Li X, Burgess S, et al. Surfactant protein D is a causal risk factor for COPD: results of Mendelian randomisation. Eur Respir J, 2017, 50(5): pii: 1700657.
49. Hassan NB, Abo-ElMagd NM, Ahmed NO. Neutrophil CD64 expression and other laboratory biomarkers in discriminating bacterial versus non bacterial acute exacerbation chronic obstructive pulmonary disease. Egypt J Immunol, 2018, 25(1): 171-179.
50. Titova E, Aune MW, Fonn K, et al. Neutrophil CD64 expression as a diagnostic marker in patients hospitalized with exacerbations of COPD: a prospective observational study. Lung, 2015, 193(5): 717-724.
51. Mendy A, Forno E, Niyonsenga T, et al. Blood biomarkers as predictors of long-term mortality in COPD. Clin Respir J, 2018, 12(5): 1891-1899.
52. Mohamed-Hussein A, Aly S, Zahran A, et al. Neutrophil CD64 versus neutrophil/lymphocyte ratio (NLR) as markers predicting in-hospital outcome in acute exacerbation of COPD. Eur Respir J, 2017, 50: PA4095.
53. Gunay E, Sarinc Ulasli S, Akar O, et al. Neutrophil-to-lymphocyte ratio in chronic obstructive pulmonary disease: a retrospective study. Inflammation, 2014, 37(2): 374-380.
54. Leung JM, Obeidat M, Sadatsafavi M, et al. Introduction to precision medicine in COPD. Eur Respir J, 2019, 53(4): pii: 1802460.
55. Washko GR, Parraga G. COPD biomarkers and phenotypes: opportunities for better outcomes with precision imaging. Eur Respir J, 2018, 52(5): pii: 1801570.

Previous Article
慢性阻塞性肺疾病急性加重期生物標志物的研究進展
Next Article
高致病性冠狀病毒對抗宿主干擾素抗病毒系統作用的研究進展

Chinese Journal of Respiratory and Critical Care Medicine

中性粒細胞與淋巴細胞比值在慢性阻塞性肺疾病中的應用研究進展

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content